Patients’ and oncologists’ preferences for second-line maintenance PARP inhibitor therapy in epithelial ovarian cancer | Zendy

Rebecca L. Stone | Zendy; M. Janelle CambronMellott | Zendy; Kathleen Beusterien | Zendy; Martine C. Maculaitis | Zendy; Stephanie Ritz | Zendy; Emily Mulvihill | Zendy; Matthew Monberg | Zendy; Elizabeth A. Szamreta | Zendy; Suvina Amin | Zendy; Kimmie McLaurin | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Patients’ and oncologists’ preferences for second-line maintenance PARP inhibitor therapy in epithelial ovarian cancer

Author(s) -

Rebecca L. Stone,

M. Janelle CambronMellott,

Kathleen Beusterien,

Martine C. Maculaitis,

Stephanie Ritz,

Emily Mulvihill,

Matthew Monberg,

Elizabeth A. Szamreta,

Suvina Amin,

Kimmie McLaurin

Publication year - 2021

Publication title -

future oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.857

H-Index - 72

eISSN - 1744-8301

pISSN - 1479-6694

DOI - 10.2217/fon-2021-0567

Subject(s) - medicine , ovarian cancer , maintenance therapy , adverse effect , oncology , parp inhibitor , cancer , chemotherapy , disease , intensive care medicine , poly adp ribose polymerase , biochemistry , chemistry , polymerase , gene

Aim: To understand the preferences of US patients and oncologists for PARP inhibitors as second-line maintenance (2LM) for epithelial ovarian cancer. Methods: A discrete choice experiment was conducted to assess the preferences of treatment attributes. Results: The most valued attributes were risk of grade 3/4 adverse events (AEs; patients, n = 204) and progression-free survival (PFS; oncologists, n = 151). To accept a 37% increased risk of grade 3/4 AEs, PFS would need to increase by 27.9 months (patients) and 6.3 months (oncologists). The least valued attributes were dosing form/frequency (patients) and grade 3/4 anemia risk (oncologists). Conclusion: Patients' and oncologists' willingness to make benefit–risk trade-offs in the 2LM setting suggests that the PFS gains observed in selected studies of poly (ADP-ribose) polymerase inhibitors in BRCA-mutated disease are worth the toxicity risk.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research